Wed.Jan 29, 2025

article thumbnail

Sustainability in Pharmaceutical Outsourcing

PharmaTech

Pharmaceutical Technology spoke with Saharsh Davuluri, Vice-Chairman and Managing Director, Neuland Laboratories, to see how the push to sustainability is impacting contract manufacturers.

article thumbnail

Ozempic is first GLP-1 drug FDA-approved for kidney disease

pharmaphorum

Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be cleared to prevent worsening kidney disease in type 2 diabetics

FDA 94
article thumbnail

Industry Outlook 2025: Through the Lens of a Service Provider

PharmaTech

Pharmaceutical Technology spoke with Adam Sherlock, CEO of Qinecsa, about the industry trends of 2024, the future technology agenda, and M&A prospects in 2025.

article thumbnail

New FDA Approval Adds Chronic Kidney Disease to Ozempic’s Label

MedCity News

Novo Nordisks type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products. The post New FDA Approval Adds Chronic Kidney Disease to Ozempics Label appeared first on MedCity News.

FDA 95
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Lyfegen partners EVERSANA on pricing, access resource

pharmaphorum

Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment

Pharma 90

More Trending

article thumbnail

Will European PFAS ban disrupt pharma supply chains?

Pharmaceutical Technology

A proposed ban on PFAS chemicals is being challenged over concerns about potential supply chain disruption in the pharmaceutical industry.

Pharma 72
article thumbnail

Troubled 23andMe is exploring a sale of the business

pharmaphorum

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.

Sales 66
article thumbnail

FDA Approves Ozempic Indications for Reducing Risk of Kidney Failure, Cardiovascular Death

PharmaTech

Drug manufacturer Novo Nordisk said the approval establishes Ozempic as the most broadly indicated GLP-1 RA in its class.

article thumbnail

RFK Jr. denies being anti-vaccine during intense Senate confirmation

Pharmaceutical Technology

The potential secretary for Health and Human Services has been forced to defend his previous anti-vaccine stances at his senate hearing.

59
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Upperton Pharma Solutions Finalizes Construction of Sterile Manufacturing Plant

Pharmaceutical Commerce

The 7,000 square-foot GMP facility will provide formulation development support, along with analytical testing services.

article thumbnail

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn

Pharmaceutical Technology

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

59
article thumbnail

Challenges Facing Pharma Supply Chains

Pharmaceutical Commerce

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, outlines the technological obstacles that lie ahead for the industry this year.

Pharma 59
article thumbnail

FDA expands Enhertu approval to include HER2-ultralow breast cancer patients

Pharmaceutical Technology

Enhertu is projected to reach $13.9bn in sales by 2030, according to GlobalDatas Pharma Intelligence Center.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Executive hiring changes reflect a broader biotech comeback

PharmaVoice

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

Pharma 59
article thumbnail

Lyndra Therapeutics appoints Adam Sayer new CEO and president

Pharmaceutical Technology

Lyndra Therapeutics has announced the immediate appointment of Adam Sayer as its new president and CEO, succeeding Jessica Ballinger.

59
article thumbnail

A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

PharmaVoice

Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

FDA 59
article thumbnail

RFK cousin delivers broadside ahead of confirmation hearing

pharmaphorum

RFK Jr is unfit to lead the Department of Health and Human Services (HHS), according to members of his own family.

Leads 59
article thumbnail

10 Ways to Leverage Buyer Signals and Drive Revenue

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

article thumbnail

Pharma Pulse 1/29/25: USP Calls for Pharmacists to Volunteer, Regulatory Response to Abuse-Deterrent Drugs & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 59
article thumbnail

EMA abandons X in favour of rival Bluesky

pharmaphorum

The EMA has abandoned X for Bluesky, saying Elon Musk's social media platform "no longer suits our communication needs.

Media 59
article thumbnail

Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD

Pharmaceutical Technology

The approval solidifies Novo Nordisks Ozempic as the most broadly indicated GLP-1RA in the US.

FDA 59
article thumbnail

Top Pharmaceutical Trends Shaping the Future of Pharma Marketing in 2025

Pharma Marketing Network

Introduction The pharmaceutical industry is transforming at lightning speed. In 2025, pharmaceutical trends are redefining how brands connect with healthcare professionals (HCPs), patients, and stakeholders. Marketers must adapt to cutting-edge technology, personalized engagement, and regulatory shifts to stay ahead. But what exactly is shaping the future of pharma marketing this year?

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

FDA RMAT designation for Beacon’s retinitis pigmentosa treatment

Pharmaceutical Technology

The FDA has granted RMAT designation to Beacon Therapeutics gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

FDA 59
article thumbnail

FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease

PharmExec

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.

article thumbnail

Pharmacy Focuses on Prevention for the Community in Owasso, Oklahoma

Pharmacy Times

Kathy Campbell, PharmD, shares her experiences helping 4 generations of patients.

article thumbnail

Essen Health Care Selected to Test Medicare Dementia Care Model

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

Signal-Based Selling: How to Leverage 4 Key Buying Signals

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

article thumbnail

Common Osteoporosis Treatments May Offer Protection Against COVID-19

Pharmacy Times

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.

article thumbnail

Roche Appoints Wafaa Mamilli as Chief Digital Technology Officer

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

A 30-Minute Infusion of Isatuximab Is Safe, Feasible in Patients with Newly Diagnosed Multiple Myeloma

Pharmacy Times

Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival.